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Objectives The purpose of this study was to investigate whether peripheral endothelial dysfunction could predict the occur-
rence of cardiovascular events in patients with heart failure (HF) with normal left ventricular ejection fraction
(HFNEF).
Background Endothelial dysfunction plays an important role in HF, but the relation between peripheral endothelial dysfunc-
tion and prognosis in HFNEF remains unknown.
Methods We conducted a prospective cohort study of 321 patients with HFNEF. We evaluated cardiac function by echo-
cardiography measuring the ratio of early transmitral flow velocity to tissue Doppler early diastolic mitral annular
velocity (E/e’), noninvasively assessed peripheral endothelial function by reactive hyperemia-peripheral arterial
tonometry (RH-PAT) as the RH-PAT index (RHI), and followed cardiovascular events.
Results A total of 59 patients had a cardiovascular event. Kaplan-Meier analysis demonstrated a significantly higher probabil-
ity of cardiovascular events in the low RHI group than in the high RHI group (mean follow-up: 20 months; log-rank
test: p  0.001). Multivariate Cox hazard analysis identified RHI (per 0.1) (hazard ratio [HR]: 0.80; 95% confidence
interval [CI]: 0.67 to 0.94; p  0.007), E/e’ (Ln[E/e’] [per 0.1]) (HR: 1.15; 95% CI: 1.04 to 1.26; p  0.006), and
B-type natriuretic peptide (BNP) (Ln[BNP] [per picogram/milliliter]) (HR: 1.81; 95% CI: 1.44 to 2.28; p  0.001) as
independent predictors of cardiovascular events. The C-statistics for cardiovascular events substantially increased
when the RHI was added to the HFNEF prognostic 5 factors (PF5)—age, diabetes, New York Heart Association classi-
fication, HF hospitalization history, and left ventricular ejection fraction—which were identified in the I-PRESERVE
(Irbesartan in Heart Failure with Preserved Ejection Fraction Study) (PF5 alone: 0.671; PF5  RHI: 0.712). The net
reclassification index was significant after addition of the RHI (19.0%, p  0.01).
Conclusions Peripheral endothelial dysfunction independently correlated with future cardiovascular events, adding incremental
clinical significance for risk stratification in patients with HFNEF. (Endothelial Dysfunction Assessed by Reactive Hyperemia
Peripheral Arterial Tonometry and Heart Failure with Preserved Left Ventricular Ejection Fraction; UMIN000002640)
(J Am Coll Cardiol 2012;60:1778–86) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.036Approximately 50% of patients with heart failure (HF) have
normal or preserved left ventricular ejection fraction
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October 30, 2012:1778–86 Peripheral Endothelial Dysfunction in HFNEFreduced LVEF (HFREF) (1,3). Effective treatments for patients
with HFNEF have not been established because the precise
mechanism underlying HFNEF remains unclear. Left
ventricular diastolic dysfunction (LVDD) plays an im-
portant role in patients with HFNEF (4), and HFNEF
could be due to structural and molecular abnormalities of
the cardiovascular system. These abnormalities include
myocardial ischemia, cardiomyocyte hypertrophy, cardiac
inflammation (5), and ventricular-vascular stiffening, in part
due to the reduced effects of nitric oxide and impaired
endothelial function (6). Borlaug et al. (7) recently demon-
strated that global cardiovascular reserve functions, including
endothelial function, are impaired in subjects with HFNEF who
have hypertension.
See page 1787
Impairment of coronary and peripheral circulation with
endothelial dysfunction has been shown to be involved in
the pathogenesis of HF, mainly HFREF. Coronary endo-
thelial function is impaired in HFREF (8). Several studies
have reported that peripheral endothelial dysfunction is
associated with the severity of HF symptoms and clinical
outcome in patients with HFREF (9,10). Vascular dysfunc-
tion leading to increased vascular stiffness and resistance
with elevated blood pressure has been proposed as a poten-
tial and important noncardiac factor in the pathogenesis of
acute HF syndrome (AHFS) as the clinical manifestation in
many patients with HFNEF (11).
In contrast to patients with HFREF, the factors associ-
ated with clinical outcome remain to be fully understood in
patients with HFNEF. The I-PRESERVE (Irbesartan in
Heart Failure with Preserved Ejection Fraction Study) dem-
onstrated that age, presence of diabetes mellitus (DM), pres-
ence of a previous hospitalization for HF, N-terminal pro-B-
type natriuretic peptide (NT-proBNP), and LVEF were
associated with adverse outcomes in patients with HFNEF
(12), although the relation between peripheral endothelial
dysfunction and prognosis in HFNEF remains unknown.
The main hypothesis of this study was that peripheral
endothelial dysfunction could be a prognostic factor for
future cardiovascular events in patients with HFNEF in the
prospective cohort study.
Methods
Study population. The study included patients who pre-
sented with signs or symptoms of HF and were referred for
diagnosis or treatment of HF at Kumamoto University
Hospital and Yokohama City University Medical Center
between August 2006 and August 2011 (n  762). All of
he patients were free of noncardiac causes of HF-like
ymptoms, such as chronic obstructive pulmonary disease
nd end-stage renal disease with hemodialysis. The exclu-
ion criteria included reduced LVEF (50, n  280), acute
oronary syndromes (n  56), severe valvular heart disease t(n  29), hypertrophic obstruc-
tive cardiomyopathy (n  16),
significant inflammatory disease
(n  3), and neoplasms (n  4).
We applied the diagnostic cri-
teria of the European Working
Group to HFNEF (13). We ex-
cluded 53 patients with HFNEF
who did not meet these diagnos-
tic criteria. Finally, 321 patients
with HFNEF were enrolled in
the present study (Fig. 1).
During the same study period,
age-, gender-, rate of hypertension,
and DM-matched patients with
normal LVEF who did not present
with HF symptoms and had never
been diagnosed or treated for HF
were also enrolled as patients with-
out HF (n  173).
The study complied with the
eclaration of the Helsinki regard-
ng investigation in humans, was
pproved by each institutional re-
iew committee, and was conducted
n accordance with the guidelines of
he ethics committee at each institu-
ion. Written informed consent was
btained from all patients. This
tudy was registered at the Univer-
ity Hospital Medical Information
etwork (UMIN) Clinical Trials
egistry (UMIN000002640).
ssessment of endothelial
unction by reactive hyperemia-
eripheral arterial tonometry.
eripheral endothelial function was
ssessed by reactive hyperemia-
eripheral arterial tonometry (RH-
AT) using the EndoPAT2000
ystem (Itamar Medical, Caesarea,
srael), as described previously
14). RH-PAT measurement is
argely operator independent,
nd a computerized algorithm
ith an online system automatically calculates the RH-PAT
ndex (RHI); thus, there is minimal interoperator and
ntraoperator variability. RH-PAT studies were performed
hen patients were in stable, compensated condition after
mplementing medical therapies for HF and in the fasting
tate in the early morning before taking any medications.
he RH-PAT value that reflected the extent of RH was
alculated as the ratio of the average pulse amplitude of
AT signal over a 1-minute time interval starting 1.5
inutes after cuff deflation (control arm, A; study arm, C)
Abbreviations
and Acronyms
AHFS  acute heart failure
syndrome
BMI  body mass index
BNP  B-type natriuretic
peptide
CI  confidence interval
DM  diabetes mellitus
E/e’  ratio of early
transmitral flow velocity to
tissue Doppler early
diastolic mitral annular
velocity
eGFR  estimated
glomerular filtration rate
HF  heart failure
HFNEF  heart failure with
normal left ventricular
ejection fraction
HFREF  heart failure with
reduced left ventricular
ejection fraction
HR  hazard ratio
LV  left ventricular
LVDD  left ventricular
diastolic dysfunction
LVEF  left ventricular
ejection fraction
NRI  net reclassification
index
NT-proBNP  N-terminal
pro-B-type natriuretic
peptide
NYHA  New York Heart
Association
OR  odds ratio
PF5  HFNEF prognostic 5
factors
RHI  reactive hyperemia-
peripheral arterial
tonometry index
RH-PAT  reactive
hyperemia-peripheral
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Peripheral Endothelial Dysfunction in HFNEF October 30, 2012:1778–862.5-minute time period before cuff inflation (baseline)
(control arm, B; study arm, D) (Fig. 2). The RH-PAT value
was calculated by the following equation: RH-PAT value
(C/D)/(A/B). We used a natural logarithmic transforma-
tion of the RH-PAT value to calculate the RHI: RHI 
Ln{[RH-PAT ratio] · [0.226 · Ln(baseline) 0.2]} (14,15).
revious studies have demonstrated that RH-PAT technol-
gy has excellent reproducibility (16,17) (Online Fig. 1).
ollow-up. After the assessment of endothelial function by
H-PAT, patients with HFNEF were followed prospec-
ively every month at the outpatient clinics until September
011 or an endpoint occurred. The endpoint was a com-
osite of cardiovascular death, nonfatal myocardial infarc-
ion, unstable angina pectoris, nonfatal ischemic stroke,
ospitalization for HF decompensation, or coronary revas-
ularization (definition in the Online Appendix). Cardio-
ascular events were ascertained from a review of medical
ecords and confirmed by direct contact with the patients,
heir families, and physicians. For subjects who had more
han 2 cardiovascular events, only the first event was
Figure 1 Flow Chart Showing the Protocol
Used for Enrollment of Patients With HFNEF
BNP  B-type natriuretic peptide; E/e’  the ratio of early transmitral flow
velocity to tissue Doppler early diastolic mitral annular velocity; HF  heart fail-
ure; HFNEF  heart failure with normal left ventricular ejection fraction; LVEF 
left ventricular ejection fraction; RH-PAT  reactive hyperemia peripheral arte-
rial tonometry.onsidered in the analysis. We used the median value of theRHI to divide patients with HFNEF into low and high
RHI groups.
Statistical analysis. Continuous variables with normal dis-
tribution were expressed as the mean  SD. Continuous
variables with skewed distribution were summarized as the
median (interquartile range). Estimates of the C-statistic for
Cox proportional hazards regression models were calculated
(18–20). The comparison of C-statistics was estimated after
the addition of RHI, B-type natriuretic peptide (BNP), and
the ratio of early transmitral flow velocity to tissue Doppler
early diastolic mitral annular velocity (E/e’) to the HFNEF
prognostic 5 factors (PF5), which were identified in the
I-PRESERVE (12), including age, presence of DM, pres-
ence of a previous hospitalization for HF, New York Heart
Association (NYHA) classification, and LVEF. We also
examined whether the addition of RHI, BNP, and E/e’
improved the discriminatory power of the model. The
proportional hazards assumption was confirmed by Schoe-
nfeld’s global test. The calibration of Cox regression models
also was assessed by the Grønnesby and Borgan calibration
test (21).
Figure 2 Representative RH-PAT Signals
(A) RH-PAT index (RHI) was calculated by the following equation: RHI  Ln{[(C/
D)/(A/B)] · [0.226 · Ln(baseline)  0.2]}. The representative results of RH-PAT
examination of the patient with heart failure with normal left ventricular ejection
fraction (HFNEF) without (B) and with (C) a cardiovascular event. RH-PAT exam-
ination was performed at the study entry point in patients in a stable and com-
pensated condition. HFNEF  heart failure with normal left ventricular ejection
fraction; RH-PAT  reactive hyperemia-peripheral arterial tonometry; RHI  RH-
PAT index.
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October 30, 2012:1778–86 Peripheral Endothelial Dysfunction in HFNEFThe incremental effect of adding the RHI to the PF5 for
predicting future cardiovascular events was evaluated using
the net reclassification index (NRI) as previously described
(22). A p value 0.05 was considered statistically signifi-
cant. An expanded Methods section is available in the
Online Appendix.
Results
Study population. A total of 321 patients with HFNEF
and 173 patients without HF were enrolled in this study.
Patients with HFNEF had a higher body mass index (BMI)
and heart rate than patients without HF (Table 1). Patients
with HFNEF had lower levels of estimated glomerular
filtration rate (eGFR) and higher levels of BNP and
high-sensitivity C-reactive protein compared with patients
without HF. The E/e’ ratio was higher, left atrial diameter
was larger, and left ventricular (LV) mass index was higher
in patients with HFNEF compared with patients without
Clinical and Echocardiographic Characteristics of the Study PopulaTable 1 Clinical and Echocardiographic Characteristics of the S
Patients Without HF
(n  173)
Patients W
(n  3
Age, yrs 71 9 72
Female 83 (48) 161 (50)
BMI, kg/m2 23.4 3.1 24.3
Waist circumference, cm 87 9 89
NYHA functional class II/III, IV — 246/
CAD 85 (49) 145 (45)
Atrial fibrillation — 102 (32)
Hypertension 143 (83) 268 (83)
Hypercholesterolemia 100 (58) 168 (52)
DM 67 (39) 140 (44)
Metabolic syndrome 79 (46) 139 (43)
Current smoker 20 (12) 32 (10)
Heart rate, beats/min 69 11 72
BNP, pg/ml 25 (14–50) 121 (33–
Hemoglobin, g/dl 13.0 1.5 12.8
eGFR, ml/min/1.73 m2 68 18 60
Severe renal dysfunction
(eGFR  30 ml/min/1.73 m2)
1 (0.6) 20 (6)
hsCRP (mg/dl) 0.05 (0.03–0.15) 0.09 (0.0
LVEF 65 5 63
E/e’ 9.9 (8.4–11.6) 16.2 (15.
Left atrial diameter, mm 36.3 5.7 40.8
LV mass index, g/m2 107 (93–133) 130 (105
Medications
Beta-blocker 55 (32) 166 (52)
ACEIs or ARBs 85 (49) 210 (65)
Calcium-channel blockers 89 (51) 171 (53)
Nitrates 27 (16) 57 (18)
Diuretics 14 (8) 110 (34)
Spironolactone 3 (2) 50 (16)
Statins 109 (63) 181 (56)
Aspirin 111 (64) 193 (60)
Values are mean  SD, median (25th to 75th percentile range), or n (%). The p values represent
ACEI angiotensin-converting enzyme inhibitor; ARB angiotensin II receptor blocker; BMI bo
GFR  estimated glomerular filtration rate; HFNEF  heart failure with normal ejection fraction; hsCRP 
YHA  New York Heart Association.HF (Table 1). Of 321 patients with HFNEF, patients in
the low RHI group (below median, cutoff value: 0.49) had
higher NYHA classes than those in the high RHI group
(above median) (Table 1).
Endothelial function in patients with HFNEF. The
RHI was significantly lower in patients with HFNEF
compared with patients without HF (0.53 0.20 vs. 0.64
0.20; p  0.001) (Fig. 3). Stepwise backward multivariate
logistic regression analysis among various clinical factors
demonstrated that BMI (odds ratio [OR]: 1.08; 95%
confidence interval [CI]: 1.02 to 1.15; p  0.01), eGFR
OR: 0.98; 95% CI: 0.97 to 0.99; p  0.002), heart rate
OR: 1.01; 95% CI: 1.00 to 1.03; p  0.04), and RHI (per
.1) (OR: 0.77; 95% CI: 0.70 to 0.85; p  0.001) were
ndependently correlated with the presence of HFNEF
mong the age-, gender-, and rate of hypertension or
M-matched subjects with normal LVEF and patients
ith HFNEF (Hosmer-Lemeshow chi-square  14.8 and
Population
NEF
p Value
Low RHI Group
(n  160)
High RHI Group
(n  161) p Value
0.27 72 10 71 9 0.82
0.64 77 (48) 84 (52) 0.50
0.006 24.2 3.3 24.4 3.9 0.56
0.05 89 10 89 10 0.95
— 107/53 139/22 0.001
0.40 77 (48) 68 (42) 0.29
— 58 (36) 44 (27) 0.09
0.81 129 (81) 139 (86) 0.18
0.25 91 (57) 77 (48) 0.09
0.29 71 (44) 69 (43) 0.82
0.61 73 (46) 66 (41) 0.40
0.58 19 (12) 13 (8) 0.26
0.03 73 18 71 18 0.40
0.001 166 (43–330) 106 (30–275) 0.07
0.12 12.9 1.7 12.6 1.9 0.16
0.001 61 21 60 18 0.71
0.003 11 (7) 9 (6) 0.63
) 0.001 0.10 (0.05–0.24) 0.08 (0.04–0.18) 0.17
0.001 62 7 63 6 0.35
) 0.001 16.3 (15.0–19.1) 16.2 (15.1–18.6) 0.71
0.001 40.9 6.8 40.8 7.4 0.96
0.001 125 (105–154) 136 (110–161) 0.14
0.001 87 (54) 79 (49) 0.34
0.001 104 (65) 106 (66) 0.88
0.70 83 (52) 88 (55) 0.62
0.54 29 (18) 28 (17) 0.86
0.001 64 (40) 46 (29) 0.03
0.001 28 (18) 22 (14) 0.34
0.17 92 (58) 89 (55) 0.69
0.38 99 (62) 94 (58) 0.52
risons of patients with HFNEF versus patients without HF or low versus high RHI group.
s index; BNP B-type natriuretic peptide; CAD coronary artery disease; DM diabetes mellitus;tiontudy
ith HF
21)
10
3.6
10
75
18
302)
1.8
20
4–0.22
6
0–18.8
7.1
–157)
compa
dy mashigh-sensitivity C-reactive protein; LV  left ventricular; LVEF  left ventricular ejection fraction;
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Peripheral Endothelial Dysfunction in HFNEF October 30, 2012:1778–86p  0.06). Even after the forced adjustment for BMI,
eGFR, and the presence of hypertension and DM, the RHI
was significantly correlated with the presence of HFNEF
(OR: 0.77; 95% CI: 0.70 to 0.85; p  0.001; Hosmer-
emeshow chi-square  12.6 and p  0.13). All baseline
edications were not significantly associated with endothe-
ial dysfunction (low RHI group) in patients with HFNEF
ccording to a simple logistic regression analysis (Online
able 1).
ollow-up. The data of 320 patients with HFNEF were
vailable for analyzing cardiovascular events. One patient
as lost to follow-up. The follow-up period was 1 to 57
onths (mean: 20 months). Overall, 59 cardiovascular
vents were recorded in patients with HFNEF during the
ollow-up period. Details of the cardiovascular events are as
ollows: cardiovascular death (n  6), nonfatal myocardial
nfarction (n  1), ischemic stroke (n  4), hospitalization
or HF decompensation (n  32), unstable angina pectoris
n  10), and coronary revascularization (n  6). The
requency of cardiovascular events was significantly higher
n the low RHI group (below median, cutoff value: 0.49)
ompared with the high RHI group (above median) (n 45
s. n  14, p  0.001). Kaplan-Meier analysis demon-
trated a significantly higher probability of cardiovascular
vents in the low RHI group compared with the high RHI
roup (log-rank test: p  0.001) (Table 2, Fig. 4A).
ox proportional hazards analysis and C-statistics for
ardiovascular events. The results of the univariate and
ultivariate Cox proportional hazards analyses for cardio-
ascular events are summarized in Table 3. Stepwise mul-
ivariate Cox proportional hazard analysis identified RHI
per 0.1) (hazard ratio [HR]: 0.80; 95% CI: 0.67 to 0.94;
Figure 3 RHI in Patients With HFNEF and Patients Without HF
Bars represent averages of the RH-PAT index (RHI) in each group. T-bars indi-
cate SD. HF  heart failure; HFNEF  heart failure with normal left ventricular
ejection fraction; RHI  RH-PAT index. 0.007), E/e’ (Ln[E/e’] [per 0.1]) (HR: 1.15; 95% CI: r.04 to 1.26; p  0.006), and BNP (Ln[BNP] [per
icogram/milliliter]) (HR: 1.81; 95% CI: 1.44 to 2.28; p 
.001) as independent predictors of future cardiovascular
vents (Table 3). By using the 5 forced inclusion models
ith various clinical parameters in the multivariate Cox
azard analysis, the RHI still significantly predicted cardio-
ascular events (Table 3). As shown in Figure 4B, the
ombination of RHI and BNP identified subgroups with a
ignificantly different probability of cardiovascular events
log-rank test: p  0.001). In both the low and high BNP
roups, the low RHI group had a significantly higher
robability of cardiovascular events compared with the high
HI group (log-rank test: p  0.01 and p  0.02,
espectively). Even in patients with mild HF symptoms
NYHA class II), the low RHI group was associated with
orse outcomes than the high RHI group (log-rank test
 0.006) (Fig. 4C).
We estimated the C-statistic of PF5 alone. Separate
ncorporation of RHI, E/e’, and BNP into the PF5 in-
reased the C-statistic for prediction of future cardiovascular
vents (C-statistics: PF5 alone 0.671, PF5  RHI 0.712,
F5  E/e’ 0.700, and PF5  BNP 0.732) (Table 4).
oreover, we examined the additive usefulness of RHI to
F5 and E/e’, BNP, or both. The RHI increased the
-statistics in each model (C-statistics: PF5  E/e’ 0.700,
F5  E/e’  RHI 0.737, PH5  BNP 0.732, PF5 
BNP  RHI 0.753, PF5  E/e’  BNP 0.742, PF5 
/e’  BNP  RHI 0.761) (Table 4). The addition of
HI, E/e’, and BNP to PF5 resulted in a significant
ncrease in the C-statistics from 0.671 to 0.761 (p  0.02).
The Schoenfeld’s tests indicated that the proportional
azards assumptions were appropriate (p  0.95). We also
onfirmed good calibration for the analysis by using Grøn-
esby and Borgan (21) statistics (p  0.30).
et reclassification index. We reclassified the risk of PF5
or the patients with HFNEF. The NRI was significant
ith the inclusion of the RHI (8.8% for patients without
ardiovascular events, 10.2% for those with cardiovascular
vents, and 19.0% overall, p  0.01) (Table 5).
Cardiovascular Events in PatientsWith HFNEF With Low or High RHITable 2 Cardiova cular Events in PatientsWith HFNEF With Low or High RHI
Low RHI Group
(n  160)
High RHI Group
(n  160)
p
Value
Total cardiovascular events 45 (28.1) 14 (8.8) 0.001
Cardiovascular death 5 (3.1) 1 (0.6) 0.11
Nonfatal myocardial infarction 0 (0) 1 (0.6) 0.32
Unstable angina 8 (5.0) 2 (1.3) 0.15
Ischemic stroke 2 (1.3) 2 (1.3) 0.99
Hospitalization for HF
decompensation
26 (16.3) 6 (3.8) 0.002
Coronary revascularization 4 (2.5) 2 (1.3) 0.48
Values are n (%). Significance was assessed by the log-rank test.
HF  heart failure; HFNEF  heart failure with normal left ventricular ejection fraction; RHI 
eactive hyperemia-peripheral arterial tonometry index.
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October 30, 2012:1778–86 Peripheral Endothelial Dysfunction in HFNEFDiscussion
This is the first report to reveal a significant association
between peripheral endothelial dysfunction and adverse
cardiovascular outcomes in patients with HFNEF. Signifi-
cant endothelial dysfunction was demonstrated in patients
with HFNEF, and the RHI was significantly correlated
with the presence of HFNEF, independently of various
comorbid factors and diseases. Endothelial dysfunction,
BNP, and E/e’ were identified as independent predictors of
future cardiovascular events in patients with HFNEF. The
addition of endothelial function as assessed by the RHI to
the previously described HFNEF prognostic factors with
Figure 4 Kaplan-Meier Analysis
Kaplan-Meier analysis for the probability of cardiovascular events in patients
with high or low RHI (A), in subgroups of patients with high or low RHI and
B-type natriuretic peptide (BNP) (B), and in subgroups of New York Heart Asso-
ciation (NYHA) class II patients with high or low RHI (C). On the basis of a cut-
off point: RHI 0.49 (median), BNP 100 pg/ml. BNP  B-type natriuretic
peptide; NYHA  New York Heart Association; RHI  RH-PAT index.BNP and E/e’ improved risk stratification in patients withHFNEF, as indicated by a substantial increase in the
C-statistics and a significant NRI.
Patients with HFNEF represent a heterogeneous popu-
lation, and the precise mechanism underlying HFNEF is
not fully understood. The I-PRESERVE demonstrated
that age, presence of DM, presence of a previous hospital-
ization for HF, NT-proBNP, and LVEF were associated
with adverse clinical outcome in patients with HFNEF
(12); however, the determinants of prognosis in patients
with HFNEF remain largely unexplored.
Endothelial dysfunction has been shown to be involved in
the pathogenesis of HF, mainly HFREF. Several studies
have reported that peripheral endothelial dysfunction is
associated with clinical outcome in patients with HFREF
(10). Borlaug et al. (23) recently reported that subjects with
HFNEF had limited arterial vasodilatory response to exer-
cise, which might impair cardiac output reserve under stress
conditions and demonstrated that global cardiovascular
reserve functions, including peripheral endothelial function,
are impaired in subjects with HFNEF (7). However, no
previous report has discussed the association between pe-
ripheral endothelial function and adverse clinical outcome in
patients with HFNEF. In the present study, we first
reported that peripheral endothelial function assessed by
RH-PAT significantly correlates with future cardiovascular
events in patients with HFNEF. Peripheral endothelial
function is still an independent predictor after adjusting
various clinical parameters. The NRI was significant when
the RHI was added to the PF5. The present study also
demonstrated that peripheral endothelial function, BNP,
and E/e’ were independent predictors of future cardiovas-
cular events in patients with HFNEF. The combination of
these parameters adding to PF5 significantly increased the
C-statistics and may be useful to improve risk stratification
in patients with HFNEF.
The present study also demonstrated that BNP inde-
pendently correlated with future cardiovascular events in
patients with HFNEF. This result was consistent with
the result of a recent report of NT-proBNP from the
I-PRESERVE (12). BNP was still an independent pre-
dictor of adverse outcomes in patients with HFNEF or
HFREF.
Moreover, the present study identified E/e’ as an inde-
pendent predictor of future cardiovascular events in patients
with HFNEF. E/e’ has been used as an index of LV filling
pressure and abnormal LV relaxation (24). LVDD plays an
important role in patients with HFNEF (4). Prior studies
have demonstrated that elevated LV filling pressure or
LVDD was associated with adverse outcomes in patients
with HFREF (25–27) or community subjects with nor-
mal LVEF and without HF (2); however, few previous
reports showed the relationship between LVDD and
adverse clinical outcomes in patients with HFNEF. Ren
et al. (28) reported that the presence of asymptomatic
LVDD could predict subsequent hospitalization for HF
events in patients with coronary heart disease without a
metry in
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showed that elevated E/e’ after optimized medical therapy
predicts future HF events in patients with HFNEF. Our
data confirmed this result in a relative larger population.
Effective treatments for patients with HFNEF have not
been established because the precise mechanisms underlying
HFNEF remain unclear. HFNEF often has been shown to
cause AHFS, and the high-risk population with AHFS
after discharge has not been clarified. To achieve the better
postdischarge outcomes in patients hospitalized for AHFS,
optimizing treatments in the early postdischarge period will
require the improvement of risk stratification and patient
Cox Proportional Hazards Analysis for Future Cardiovascular EventsTable 3 Cox Proportional Hazards Analysis for Future Cardiova
Variable
Univariate Regression
HR 95% CI p Value
Age (per year) 1.00 0.98–1.03 0.81
Female 0.98 0.59–1.63 0.94
Body mass index (per kg/m2) 1.00 0.93–1.08 0.99
Waist circumferences (per cm) 1.00 0.97–1.02 0.77
NYHA functional class III or IV vs. II 4.18 2.50–6.99 0.001
Previous history of decompensated
HF hospitalization (yes)
2.92 1.74–4.89 0.001
CAD (yes) 1.13 0.68–1.89 0.63
Atrial fibrillation (yes) 2.25 1.35–3.76 0.002
Diabetes mellitus (yes) 1.18 0.71–1.96 0.53
Metabolic syndrome (yes) 0.93 0.56–1.56 0.79
Current smoker (yes) 1.00 0.43–2.32 0.99
Heart rate (per beats/min) 1.02 1.00–1.03 0.02
Systolic blood pressure (per mm Hg) 0.99 0.98–1.00 0.08
Diastolic blood pressure (per mm Hg) 0.98 0.96–1.00 0.07
LDL cholesterol (per mg/dl) 1.00 0.99–1.00 0.25
HDL cholesterol (per mg/dl) 0.99 0.97–1.00 0.13
Ln (Triglycerides) (per mg/dl) 0.80 0.46–1.41 0.44
Ln (BNP) (per pg/ml) 1.89 1.52–2.36 0.001
Hemoglobin (per g/dl) 0.96 0.84–1.11 0.60
eGFR (per ml/min/1.73 m2) 0.99 0.98–1.01 0.38
hsCRP (mg/dl) 1.37 0.94–2.01 0.10
LVEF (per %) 0.93 0.89–0.97 0.001
Ln (E/e’) (per 0.1) 1.16 1.04–1.29 0.009
RHI (per 0.1) 0.72 0.61–0.85 0.001
Variable
M
Model 2
HR 95% CI p Value HR
NYHA functional class III or IV vs. II 1.76 0.86–3.64 0.12 1.97 0
Previous history of decompensated
HF hospitalization (yes)
0.76 0.38–1.53 0.44 0.68 0
Atrial fibrillation (yes) — 1.54 0
Heart rate (per beats/min) —
Ln (BNP) (per pg/ml) 1.68 1.30–2.19 0.001 1.63 1
LVEF (per %) —
Ln (E/e’) (per 0.1) 1.11 1.02–1.21 0.02 1.13 1
RHI (per 0.1) 0.80 0.67–0.95 0.01 0.82 0
Not selected indicates the backward algorithm selection did not reach the 0.10 signifi
model.
CI  confidence interval; HR  hazard ratio; RHI  reactive hyperemia peripheral arterial tonotriage during the compensated condition of HF symptoms(30). HFNEF could be due to structural and molecular
abnormalities of the cardiovascular system, including cardiac
and noncardiac factors such as vascular functions (7). The
prognostic impact of the RHI in patients with HFNEF
suggests that endothelial dysfunction may not be a passive
finding, but rather that endothelial function may play an
active and important pathophysiologic role in HFNEF.
This in turn supports the concept that endothelial dysfunction
may be a novel therapeutic target in HFNEF. To determine
the molecular mechanisms of endothelial dysfunction in pa-
tients with HFNEF, further clinical and experimental studies
are required, and we need to develop the therapeutic strategy
atients With HFNEFr Events in Patients With HFNEF
Stepwise Backward
Multivariate Regression
Multivariate Regression Using
Forced Inclusion Model 1
R 95% CI p Value HR 95% CI p Value
Not selected 1.00 0.97–1.02 0.87
Not selected —
Not selected —
Not selected —
Not selected 2.41 1.18–4.94 0.02
Not selected 1.20 0.61–2.35 0.60
Not selected —
Not selected —
Not selected 1.05 0.62–1.78 0.85
Not selected —
Not selected —
Not selected —
Not selected —
Not selected —
Not selected —
Not selected —
Not selected —
1 1.44–2.28 0.001 —
Not selected —
Not selected —
Not selected —
Not selected 0.96 0.92–1.00 0.07
5 1.04–1.26 0.006 —
0 0.67–0.94 0.007 0.82 0.69–0.97 0.02
iate Regression Using Forced Inclusion
l 3 Model 4 Model 5
I p Value HR 95% CI p Value HR 95% CI p Value
14 0.07 1.76 0.85–3.66 0.13 1.68 0.81–3.51 0.17
39 0.28 0.72 0.35–1.48 0.37 0.73 0.36–1.48 0.38
68 0.13 — —
1.01 1.00–1.02 0.15 —
13 0.001 1.67 1.29–2.17 0.001 1.64 1.26–2.14 0.001
— 0.97 0.93–1.02 0.24
24 0.01 1.11 1.02–1.22 0.02 1.11 1.02–1.21 0.02
97 0.02 0.80 0.68–0.94 0.008 0.80 0.68–0.95 0.01
level, when each independent variable was once included into the stepwise regression
dex; other abbreviations as in Table 1.in Pscula
H
1.8
1.1
0.8
ultivar
Mode
95% C
.94–4.
.33–1.
.88–2.
—
.25–2.
—
.03–1.
.69–0.
cancefor improving endothelial dysfunction in HFNEF.
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October 30, 2012:1778–86 Peripheral Endothelial Dysfunction in HFNEFStudy limitations. First, endothelial function in HFNEF
ay be related to a metabolic risk profile, but the results of
case-control observational study cannot prove causality.
mpairment of endothelial function in HFNEF may be a
esult of progression to HF. Measurement of plasma neu-
ohormones or exercise oxygen uptake would help to clarify
he pathophysiological link between endothelial function
nd HFNEF. Further study is needed. Second, patients
ith HFNEF were referred to 2 tertiary centers, and RHI
easurements were performed in a stable compensated state
fter treatment. These results might have referral bias and
ere applicable to such stable patients with HFNEF. The
athophysiological and prognostic importance of endothe-
ial dysfunction in AHFS should be discussed in a further
tudy. Third, the sample size was small, and the design was
2-center study in Japan, resulting in the more predomi-
antly male population and the better prognosis compared
ith that found in Western studies. Therefore, a large
ultiracial and multicenter study is required to confirm our
esults. Fourth, to select patients with HFNEF, we applied
he European Society of Cardiology consensus statement for
FNEF, which contained some limited data. Because the
iagnosis of HFNEF is practically important, we continu-
usly need to discuss and evaluate the criteria for HFNEF
o establish the definitive diagnosis. Fifth, endothelial function
ssessed by RHI measurement might be affected by various
actors in the clinical practice, which may be a limitation
o the applicability of the present findings. The present
tudy clearly demonstrated the independent prognostic
mpact of endothelial dysfunction assessed by RH-PAT
n future cardiovascular events in patients with HFNEF;
owever, the immediate clinical applicability of RH-
AT as a prognostic tool in patients with HFNEF might
e hampered by the lack of validation in a broader sample
nd lack of standardization of methodology. Further
ontinuous clinical studies are necessary.
C-Statistics for Cox ProportionalHazard Analysis to edic Futurerdiovascular Events in Patients With HFNEF
Table 4
C-Sta is ics for Cox Proportional
Hazards Analysis to Predict Future
Cardiovascular Events in Patients With HFNEF
Variable C-statistic 95% CI
Increment in
C-statistic
PF5 0.671 0.576–0.766
PF5  RHI 0.712 0.636–0.789 0.041
PF5  E/e’ 0.700 0.613–0.786
PF5  E/e’  RHI 0.737 0.663–0.811 0.037
PF5  BNP 0.732 0.649–0.814
PF5  BNP  RHI 0.753 0.680–0.826 0.021
PF5  E/e’  BNP 0.742 0.662–0.821
PF5  E/e’  BNP  RHI 0.761 0.691–0.832 0.019
BNP B-type natriuretic peptide; CI confidence interval; E/e’ the ratio of early transmitral flow
velocity to tissue Doppler early diastolic mitral annular (medial) velocity; PF5  HFNEF prognostic
5 factors that were identified in the I-PRESERVE, including age, presence of DM, presence of a
previous hospitalization for HF, NYHA classification, and LVEF; RHI reactive hyperemia-peripheral
arterial tonometry index; other abbreviations as in Table 1.Conclusions
Peripheral endothelial dysfunction assessed by RH-PAT
independently correlated with future cardiovascular events
in patients with HFNEF. In combination with BNP and
E/e’, the clinical assessment of endothelial function can
provide incremental prognostic significance, leading to im-
proved risk stratification in HFNEF.
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